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Abstract
Background
Herpes zoster is common and can have serious consequences. Additionally, emerging
data suggest an increased risk of acute cardiovascular events following herpes zoster.
However, to our knowledge, existing association studies compare outcomes between indi-
viduals and are therefore vulnerable to between-person confounding. In this study, we used
a within-person study design to quantify any short-term increased risk of acute cardiovascu-
lar events (stroke and myocardial infarction [MI]) after zoster and to assess whether zoster
vaccination modifies this association.
Methods and Findings
The self-controlled case series method was used to estimate rates of stroke and acute MI in
defined periods after herpes zoster compared to other time periods, within individuals. Par-
ticipants were fully eligible Medicare beneficiaries aged65 y with a herpes zoster diagno-
sis and either an ischemic stroke (n = 42,954) or MI (n = 24,237) between 1 January 2006
and 31 December 2011. Age-adjusted incidence ratios (IRs) for stroke and MI during prede-
fined periods up to 12 mo after zoster relative to unexposed time periods were calculated
using conditional Poisson regression. We observed a marked increase in the rate of acute
cardiovascular events in the first week after zoster diagnosis: a 2.4-fold increased ischemic
stroke rate (IR 2.37, 95% CI 2.17–2.59) and a 1.7-fold increased MI rate (IR 1.68, 95% CI
1.47–1.92), followed by a gradual resolution over 6 mo. Zoster vaccination did not appear to
modify the association with MI (interaction p-value = 0.44). We also found no evidence for a
difference in the IR for ischemic stroke between vaccinated (IR 1.14, 95% CI 0.75–1.74)
and unvaccinated (IR 1.78, 95% CI 1.68–1.88) individuals during the first 4 wk after zoster
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Conclusions
Stroke and MI rates are transiently increased after exposure to herpes zoster. We found no
evidence for a role of zoster vaccination in these associations. These findings enhance our
understanding of the temporality and magnitude of the association between zoster and
acute cardiovascular events.
Introduction
Strong and increasing evidence supports a period of increased cardiovascular risk shortly after
exposure to specific infections, with rates of myocardial infarction (MI) and stroke increased 5-
and 3-fold, respectively, following acute respiratory infection [1]. The basis for increased car-
diovascular events following acute infection is hypothesized to be endothelial dysfunction,
characterized by atheromatous plaque rupture and the development of a prothrombotic envi-
ronment [2]. As acute cardiovascular diseases (CVDs), specifically ischemic stroke and MI,
are major causes of morbidity and mortality in the US and worldwide, understanding the basis
for acute cardiovascular events and any potential for prevention becomes increasingly impor-
tant [3].
Herpes zoster results from reactivation of dormant varicella zoster virus (VZV). Herpes zos-
ter is an important disease as it affects 1 million Americans per year and is frequently compli-
cated by prolonged, severe, disabling pain, a condition called post-herpetic neuralgia (PHN)
[4,5]. Zoster-associated morbidity led to the introduction of a targeted vaccination program for
individuals aged 60 y or greater in the US in 2006. The zoster vaccine has been shown to be
effective in routine practice against incident zoster and PHN. Despite this, uptake of this vac-
cine has been disappointing (3.9%) following its introduction in the US, with important dis-
crepancies in vaccine uptake by race and by income status [6].
Recent studies have proposed that the risk of stroke may be increased in the year following
an acute episode of herpes zoster, possibly also mediated by VZV replication in arterial walls,
resulting in cerebral vasculopathy [7]. Most studies assessing the association between herpes
zoster and stroke have been limited by residual confounding because comparisons were made
between individuals who developed herpes zoster and those who did not, and these populations
have important differences in underlying vascular risk that are difficult to measure and account
for. In a previous study, our research group used the self-controlled case series (SCCS) method,
which eliminates between-person confounding, to demonstrate that there is an increased risk
of stroke in the first 6 mo following herpes zoster in the UK population and that antiviral ther-
apy might lessen this association [8]. One UK cohort study, which may be limited by residual
confounding, also suggested a longer-term increased risk of stroke and MI up to 24 y following
acute herpes zoster [9]. To our knowledge, no previous study has determined the risk of MI in
the period immediately following herpes zoster or assessed the role of zoster vaccination in the
association between zoster and acute cardiovascular events.
We used administrative claims data from older US Medicare beneficiaries to test the
hypothesis of an increased risk of stroke and MI in periods shortly following episodes of herpes
zoster and to assess whether zoster vaccination might modify this association.
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codes and CCW algorithms for cardiovascular events
used to derive the study population.
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Methods
Ethics
Ethics approval was obtained from the Centers for Medicare &Medicaid Services (CMS) (data
use agreement 21520) and from the London School of Hygiene & Tropical Medicine ethics
committee.
Data Source
Medicare is a US government health insurance plan that mainly covers healthcare costs for
individuals aged65 y, serving 15% of the US population. Coverage includes inpatient and
outpatient care, physician/preventive services, facility charges, and prescription drug benefits.
This study used Medicare administrative claims data (research identifiable files including
Medicare Provider Analysis and Review [inpatient hospital and skilled nursing facilities], out-
patient, carrier [physician/supplier], and prescription drug claims) for the period 1 January
2006 to 31 December 2011, obtained from the CMS.
Study Design
The SCCS method was used to estimate the rate of acute cardiovascular events (stroke and MI)
in defined periods after herpes zoster diagnosis compared to other time periods, within individ-
uals [10]. The SCCS approach overcomes the problem of between-person confounding inher-
ent in other observational study designs by making within-person comparisons in individuals
with zoster, whereby each case is his/her own control. Our null hypothesis was that vascular
event rates remain constant from day to day and are not affected by exposure to zoster.
Participants
The source population included all Medicare beneficiaries aged 65 y or older enrolled in Medi-
care Parts A (hospital insurance), B (supplemental medical insurance), and D (prescription
drug coverage) who had both a zoster diagnosis and a CMS Chronic Conditions Data Ware-
house flag for acute MI or stroke/transient ischemic attack (derived from the CMS’s own algo-
rithms) during the study period.
Participants were observed from the date they fulfilled the following criteria: (i) 12 mo of
continuous enrollment in Medicare Parts A and B, (ii) eligible for Medicare Part D, and (iii)
not in a health maintenance organization (HMO) (claims for beneficiaries enrolled in HMOs
are not processed by CMS; hence, their clinical data are incomplete). The criterion of 12-mo
minimum enrollment in Medicare Parts A and B was applied to enable the study of incident
rather than prevalent events. Observation was censored at the earliest of the following: (i) the
participant died, (ii) the participant joined an HMO, (iii) the participant lost eligibility for
Medicare Part A, B, or D, or (iv) the study period ended (31 December 2011).
We identified each participant’s earliest recorded zoster episode and vascular event during
the observation period and excluded individuals with evidence of vascular events or herpes zos-
ter prior to the observation period. Diagnoses of incident events were extracted from outpatient
and carrier (healthcare provider) files and from the primary diagnostic field in inpatient files.
Patients with only secondary inpatient diagnoses were excluded because of the uncertainty of
the timing of zoster or cardiovascular events, since these events were not the primary reason
for admission to hospital and hence may have occurred at any time during hospitalization.
For the stroke analyses, we additionally excluded individuals with (i) subarachnoid hemor-
rhage or established risk factors for subarachnoid hemorrhage, including cerebral aneurysms
in the circle of Willis or arteriovenous malformations, at any time during enrollment and (ii)
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encephalitis diagnoses recorded up to 12 mo after the stroke, which may represent encephalitis
initially misclassified as stroke.
Exposure
We defined incident herpes zoster as the presence of International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic code 053x (where x indicates
that the fourth/fifth digits can take any value, excluding PHN codes 05312 and 05313) with an
antiviral prescription in the 7 d before or after diagnosis. The requirement for antiviral therapy
has been shown to improve the positive predictive value of using zoster diagnosis codes to
identify incident cases [11]. Herpes zoster ophthalmicus (HZO) was identified from ICD-
9-CM code 0532x recorded up to 12 mo after the incident zoster code or, when zoster codes
were nonspecific, from either (i) acute eye infections or associated treatments within 2 wk of
the zoster diagnosis or (ii) specific non-acute eye conditions associated with zoster, e.g., con-
junctival scarring or episcleritis, recorded for the first time up to 3 mo after zoster. Exposure to
HZO was analyzed separately from exposure to herpes zoster as previous research has sug-
gested a markedly increased risk of stroke in this group [12]. In keeping with the primary zoster
definition, an accompanying antiviral claim was also required for HZO.
Herpes zoster vaccination status was ascertained from records of American Medical Associ-
ation Current Procedural Terminology (CPT) code 90736 in carrier files or US Food and Drug
Administration National Drug Codes for zoster vaccine purchase in participants’Medicare
Part D drug files. Additionally, vaccine administration records up to 7 d after purchase (CPT
code 90471 or Healthcare Common Procedure Coding System code G0377) were identified.
We estimated the date of zoster vaccination as the earlier of the date of CPT code 90736 or date
of administration. In the absence of a corresponding administration date and when no CPT
code 90736 was recorded, the vaccine purchase date was used as a proxy (procedure/adminis-
tration dates were considered better estimates of vaccination date than purchase dates).
Outcomes
We identified and classified acute cardiovascular events with specific ICD-9-CM codes for
stroke (433x1 or 434x1 [ischemic], 431 or 4329 [hemorrhagic], or 436 [nonspecific]) and MI
(410x, excluding 410x2 codes, which indicate a subsequent episode of care). As our primary
interest was in acute thrombotic cardiovascular events (ischemic stroke and MI), we excluded
hemorrhagic strokes from the primary analysis. To do this, we first designated stroke episodes
such that successive stroke codes within 28 d of each other were assumed to correspond to the
same episode. Then, for episodes containing stroke codes of different types, we used the follow-
ing hierarchy for classification: hemorrhagic codes took precedence (based on the assumption
that hemorrhagic strokes are coded more accurately than ischemic strokes), and ischemic
codes trumped nonspecific codes. Because hemorrhagic strokes could potentially result from
arterial rupture or aneurysm following VZV vasculopathy, or from a transient spike in blood
pressure (e.g., in response to zoster-associated pain), we undertook (in response to peer review)
a secondary analysis of hemorrhagic strokes. To maintain an important assumption of the
SCCS method—that recurrent outcome events within individuals are independent—we
restricted all analyses to participants’ first stroke or MI in the observation period.
Comorbidities and Demographics
For descriptive purposes, preexisting CVD (MI, stroke, transient ischemic attack, ischemic
heart disease, heart failure, or atrial fibrillation) and risk factors for CVD (hypertension, hyper-
lipidemia, diabetes, chronic kidney disease, or chronic obstructive pulmonary disease) were
Herpes Zoster, Vascular Events, and Zoster Vaccine
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identified using CMS Chronic Conditions Data Warehouse flags indicating the earliest occur-
rence of each condition. The number of unique prescriptions individuals received in the 12 mo
before their vascular event (as an indicator of overall poorer health) was determined by identi-
fying all unique prescriptions and excluding duplicate records with the same product code or
the same generic and brand names on the same date. Ethnicity was defined according to the
Social Security Administration’s master beneficiary record (based on self-report) and catego-
rized as white, black, Asian, Hispanic, and other/unknown. Participation in “state buy-in,”
whereby the state pays Medicare premiums for low-income individuals, was used as a proxy
for low income. Current age was derived from date of birth and was included in all analyses as
a time-varying covariate.
Analysis
Incidence ratios (IRs) for stroke and MI during predefined periods after exposure to zoster rel-
ative to unexposed time periods were calculated using conditional Poisson regression, adjusting
for age in 2-y bands. We defined a 12-mo exposed period starting the day after zoster diagnosis,
subdivided into five risk windows: week 1, weeks 2–4, 5–12, 13–26, and 27–52 after zoster diag-
nosis. When calculating the IR for any given risk window, the four remaining risk windows
were still considered “exposed.” All other observation time made up the baseline (unexposed)
period, with the exception of the day of and the 4 wk before zoster diagnosis. The day of zoster
diagnosis was excluded because MI or stroke records on the same day as incident zoster may
represent retrospective diagnoses. We excluded the 4 wk prior to zoster diagnosis because vas-
cular risk during this pre-zoster period may be higher or lower than in other unexposed periods
because the chances of developing and/or presenting with zoster shortly after a vascular event
may differ from those of other time periods. Removing these periods from baseline was an
attempt to avoid bias in the effect estimates that could have operated in either direction
depending on the variation in vascular risk. Fig 1 illustrates the observation period for a single
individual.
The primary analysis assessed the association between zoster (all cases, irrespective of site)
and ischemic stroke and MI separately. Additionally, the association between HZO and each
outcome was assessed. A secondary analysis of hemorrhagic strokes (excluded from the pri-
mary analysis) was conducted to examine the association between zoster and this stroke sub-
type. We undertook further analyses to explore whether vascular risk after zoster was different
in those who received the zoster vaccine versus those who did not. We defined vaccinated indi-
viduals as those who received the zoster vaccine before they developed zoster. To allow for
effective immunization, these individuals were classified as vaccinated from 30 d after receipt
of the vaccine [13]. Hence, for these stratified analyses, the adjusted start date for vaccinated
individuals was from the later of this date and their original observation start date. Unvacci-
nated individuals comprised those who did not receive the zoster vaccine and, additionally,
those who were vaccinated after their incident zoster episode and whose observation was thus
curtailed at vaccination. Because of the small numbers of individuals in the vaccinated strata,
the first two post-zoster risk windows (week 1 and weeks 2–4) were combined.
The SCCS method requires that each individual’s observation period is independent of the
event time [14]. For outcomes such as stroke or MI, which increase mortality in the short term,
this assumption may be violated. To allow for nonrandom censoring of observation due to
death as a result of a vascular event (which may lead to bias if uncorrected), an extension to the
standard SCCS method was used [15]. The extension works by conditioning explicitly on the
age at censoring in cases. Under this new model, the interpretation of the exposure effect is the
same as for the standard model, but the age effect takes on a new interpretation, representing
Herpes Zoster, Vascular Events, and Zoster Vaccine
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the combined effect of age-specific relative incidence and censoring. By introducing an addi-
tional term in the likelihood that depends on the censoring process, the independence assump-
tion is removed. The extension has been shown to successfully correct for biased estimates in
the presence of substantial post-event censoring due to mortality [16]. In addition, the primary
analysis was repeated excluding individuals who died or whose observation ended within 90 d
after their vascular event (possibly indicating death).
Standard SCCS analyses were undertaken using STATA, version 13 (StataCorp); modified
analyses accounting for event-dependent censoring were performed in R, version 3.0.2.
Results
The initial study population comprised 351,865 individuals, of whom 42,954 zoster cases with
incident ischemic stroke and 24,237 zoster cases with acute MI fulfilled the eligibility criteria
and were included in the primary analysis (Fig 2). Characteristics of these individuals are pre-
sented in Table 1. The median age at zoster diagnosis was 80 y (interquartile range [IQR] 74–
86 y), and the median observation period was 5 y (IQR 4–5 y). The majority of participants
were female (71% of zoster cases with stroke, 64% of zoster cases with MI); 89% of participants
were white (88% of strokes, 90% of MIs), 5% were black, and the remaining 6% were Asian
(2%), Hispanic (2%), or of other/unknown ethnicity (2%). In all, 16% of zoster cases had HZO;
the remaining 84% had zoster of an unspecified site. Also, 34% of cases were of low income,
and 90% had evidence of preexisting CVD before zoster diagnosis.
A small minority of cases received the zoster vaccine before developing zoster (3% of cases
with stroke, 2% of cases with MI), 6% received the vaccine after zoster diagnosis, and 91% were
unvaccinated throughout the observation period. Characteristics of individuals included in the
analyses stratified by zoster vaccination status are given in S1 Table. Vaccinated and unvacci-
nated individuals had similar median age, gender, and preexisting CVD risk profiles, although
unvaccinated individuals were more than twice as likely to be of low income and received more
prescriptions in the year leading up to their vascular event compared to vaccinated individuals.
Ethnicity data among vaccinated individuals could not be reported because some numbers
were small enough to be restricted by the CMS small-sized-cell privacy policy.
Fig 1. Pictorial representation of the self-controlled case series design, showing the observation period for a single individual.
doi:10.1371/journal.pmed.1001919.g001
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The rate of ischemic stroke was significantly increased up to 3 mo after zoster diagnosis
(any site) compared to the baseline rate: the most marked increase, 2.4-fold, was observed
within the first week (IR 2.37, 95% CI 2.17–2.59), reducing to 1.6-fold in weeks 2–4 (IR 1.55,
95% CI 1.46–1.66), 1.2-fold in weeks 5–12 (IR 1.17, 95% CI 1.11–1.22), and resolving over the
Fig 2. Identification of study participants. CCW, Chronic Conditions DataWarehouse; TIA, transient
ischemic attack.
doi:10.1371/journal.pmed.1001919.g002
Herpes Zoster, Vascular Events, and Zoster Vaccine
PLOSMedicine | DOI:10.1371/journal.pmed.1001919 December 15, 2015 7 / 15
subsequent 3 mo (weeks 13–26: IR 1.03, 95% CI 0.99–1.07; weeks 27–52: IR 1.00, 95% CI 0.96–
1.03). A similar though less marked association was observed for MI in the 3 mo after zoster
diagnosis, with a 68% increased MI rate in the first week (IR 1.68, 95% CI 1.47–1.92) compared
to baseline and a similar pattern of resolution as for stroke (weeks 2–4: IR 1.25, 95% CI 1.14–
1.37; weeks 5–12: IR 1.07, 95% CI 1.00–1.14; weeks 13–26: IR 1.02, 95% CI 0.96–1.07; weeks
27–52: IR 1.02, 95% CI 0.98–1.07) (Table 2).
Analyses restricted to cases with HZO (n = 6,971 with ischemic stroke, 3,946 with MI)
yielded associations comparable to those of the primary analysis (week 1 after HZO diagnosis:
stroke IR 2.73, 95% CI 2.22–3.35; MI IR 2.06, 95% CI 1.52–2.79) that resolved over the same
time period (Table 3).
Stratifying by zoster vaccination status revealed no evidence for a reduced IR for ischemic
stroke during the first 4 wk after zoster diagnosis among individuals who received the zoster
Table 1. Participant characteristics.
Characteristic Zoster Cases with Ischemic
Stroke (n = 42,954)
Zoster Cases with MI
(n = 24,237)
HZO 6,971 (16.2%) 3,946 (16.3%)
Age at zoster diagnosis (years) 80.4 (74.4–85.9) 79.7 (73.5–85.5)
65–69 4,330 (10.1%) 2,854 (11.8%)
70–79 16,354 (38.1%) 9,602 (39.6%)
80–89 17,568 (40.9%) 9,286 (38.3%)
90 4,702 (10.9%) 2,495 (10.3%)
Age at HZO diagnosis (years) 81.1 (75.0–86.4) 80.3 (74.2–86.2)
Gender
Male 12,672 (29.5%) 8,640 (35.6%)
Female 30,282 (70.5%) 15,597 (64.4%)
Ethnicity
White 37,943 (88.3%) 21,693 (89.5%)
Black 2,319 (5.4%) 1,151 (4.8%)
Asian 970 (2.3%) 461 (1.9%)
Hispanic 1,033 (2.4%) 555 (2.3%)
Other/unknown 689 (1.6%) 377 (1.5%)
Low incomea 14,742 (34.3%) 8,265 (34.1%)
Number of prescriptions in 12 mo
before vascular event
48 (28–77) 51 (29–81)
CVD before zosterb 38,496 (89.6%) 21,969 (90.6%)
Risk factor for CVD before zosterc 42,216 (98.3%) 23,916 (98.7%)
Total observation (years) 5.0 (4.0–5.0) 5.0 (3.8–5.0)
Zoster vaccination status
Vaccinated before zoster 1,213 (2.8%) 567 (2.3%)
Vaccinated after zosterd 2,759 (6.4%) 1,351 (5.6%)
Unvaccinated 38,982 (90.8%) 22,319 (92.1%)
Died or follow-up ended 90 d after
vascular event
4,304 (10.0%) 3,986 (16.4%)
Data are given as n (percent) or median (IQR).
aState buy-in at any time during enrollment.
bMI, stroke, transient ischemic attack, ischemic heart disease, heart failure, or atrial ﬁbrillation.
cHypertension, hyperlipidemia, diabetes, chronic kidney disease, or chronic obstructive pulmonary disease.
dIncludes 27 stroke cases and 19 MI cases who received vaccine on day of zoster diagnosis.
doi:10.1371/journal.pmed.1001919.t001
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vaccine (n = 843) (IR 1.14, 95% CI 0.75–1.74) compared to unvaccinated individuals
(n = 40,724) (IR 1.78, 95% CI 1.68–1.88) (p-value for interaction = 0.28). The overall IR com-
bining vaccinated and unvaccinated individuals for the same 4-wk post-zoster period was 1.76
(95% CI 1.67–1.86). There was no evidence that the IR for MI after zoster diagnosis varied
according to zoster vaccination status (p = 0.44): the IR in weeks 1–4 after zoster diagnosis was
1.36 (95% CI 0.78–2.39) in vaccinated individuals (n = 400) and 1.37 (95% CI 1.26–1.48) in
unvaccinated individuals (n = 23,089), similar to the combined IR of 1.37 (95% CI 1.26–1.48)
(Table 4).
The secondary analysis of hemorrhagic stroke (n = 3,109 cases) indicated a similar pattern
of increase and resolution of risk as for ischemic/nonspecific stroke, though less pronounced
and with reduced precision because of the relatively few cases. The largest increase in hemor-
rhagic stroke rate, 1.6-fold, was observed in weeks 2–4 post-zoster (IR 1.61, 95% CI 1.29–2.02),
reducing to 1.3-fold in weeks 5–12 (IR 1.30, 95% CI 1.10–1.53) and resolving thereafter.
Using the extension to the standard SCCS method to allow for nonrandom censoring of
observation gave results virtually identical to those obtained in the primary analysis
Table 2. Primary analysis: age-adjusted incidence ratios for ischemic stroke andmyocardial infarction in risk periods after zoster diagnosis.
Risk Period Number of Ischemic Stroke Cases
(n = 42,954)
Ischemic Stroke IRa (95%
CI)
Number of MI Cases
(n = 24,237)
MI IRa (95% CI)
Baseline 32,179 1 18,071 1
Risk period after
zoster
1 wk 499 2.37 (2.17–2.59)b 213 1.68 (1.47–1.92)b
2–4 wk 967 1.55 (1.46–1.66)b 470 1.25 (1.14–1.37)b
5–12 wk 1,841 1.17 (1.11–1.22)b 1,019 1.07 (1.00–1.14)c
13–26 wk 2,588 1.03 (0.99–1.07) 1,537 1.02 (0.96–1.07)
27–52 wk 3,981 1.00 (0.96–1.03) 2,459 1.02 (0.98–1.07)
aIRs age-adjusted in 2-y bands.
bp < 0.001.
cp < 0.05.
doi:10.1371/journal.pmed.1001919.t002
Table 3. Age-adjusted incidence ratios for ischemic stroke andmyocardial infarction in risk periods after herpes zoster ophthalmicus.
Risk Period Number of Ischemic Stroke Cases
(n = 6,971)
Ischemic Stroke IRa (95%
CI)
Number of MI Cases
(n = 3,946)
MI IRa (95% CI)
Baseline 5,125 1 2,891 1
Risk period after
HZO
1 wk 93 2.73 (2.22–3.35)b 43 2.06 (1.52–2.79)b
2–4 wk 177 1.77 (1.52–2.05)b 85 1.38 (1.11–1.72)b
5–12 wk 326 1.29 (1.15–1.44)b 160 1.02 (0.87–1.20)
13–26 wk 428 1.06 (0.96–1.17) 282 1.15 (1.01–1.30)c
27–52 wk 651 1.02 (0.94–1.11) 421 1.07 (0.97–1.19)
aIRs age-adjusted in 2-y bands.
bp < 0.005.
cp < 0.05
doi:10.1371/journal.pmed.1001919.t003
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(S2 Table). Further sensitivity analyses excluding potentially fatal cases also gave similar find-
ings (S3 Table).
Discussion
This study demonstrates that zoster is associated with transiently increased rates of stroke and
MI. The most marked increase was observed during the first week following zoster diagnosis,
with a 2.4-fold increased rate of ischemic stroke (IR 2.37, 95% CI 2.17–2.59) and a 1.7-fold
increased MI rate (IR 1.68, 95% CI 1.47–1.92), followed by a gradual reduction over 6 mo. The
association we observed with MI is suggestive of a systemic association rather than one local-
ized to the brain. A less marked association was observed for a secondary analysis of zoster and
hemorrhagic stroke. Uptake of the zoster vaccine was low overall, with only 9% of participants
receiving the vaccine during the study period. We found no evidence of a reduction in the IR
for ischemic stroke or MI among vaccinees in the first 4 wk after zoster diagnosis, perhaps
because of low patient numbers in the vaccinated groups, which limited the study’s power to
assess this.
We have previously demonstrated, using UK general practice data and the SCCS method,
that the rate of stroke is increased in the first 6 mo following zoster diagnosis, with the most
marked increase being observed in the first 4 wk following zoster diagnosis and the rate gradu-
ally decreasing over time [8]. We did not assess the association between zoster and MI in our
previous study, and the study period preceded the introduction of the zoster vaccine in the UK
population. To our knowledge, all of the other studies that have assessed the risk of acute car-
diovascular events following zoster have been limited by the potential for residual confounding
due to the use of cohort designs and the inherent differences between individuals who develop
zoster and those who do not develop zoster. Of these studies, two reported a 30% and a 4-fold
Table 4. Age-adjusted incidence ratios for vascular events in risk periods after zoster diagnosis, stratified by vaccination status.
Outcome Risk Period Vaccinateda Unvaccinated
Number of Cases IRb (95% CI) Number of Cases IRb (95% CI)
Ischemic stroke 843 40,724
Baseline 602 1 30,412 1
Risk period after zoster
1–4 wk 23 1.14 (0.75–1.74) 1,436 1.78 (1.68–1.88)
5–12 wk 50 1.30 (0.97–1.74) 1,778 1.17 (1.11–1.23)
13–26 wk 64 1.12 (0.86–1.46) 2,467 1.03 (0.99–1.07)
27–52 wk 81 0.97 (0.76–1.24) 3,756 1.00 (0.97–1.04)
MI 400 23,089
Baseline 272 1 17,180 1
Risk period after zoster
1–4 wk 13 1.36 (0.78–2.39) 668 1.37 (1.26–1.48)
5–12 wk 18 1.04 (0.64–1.69) 992 1.07 (1.01–1.15)
13–26 wk 37 1.49 (1.05–2.13) 1,466 1.01 (0.96–1.07)
27–52 wk 46 1.21 (0.87–1.69) 2,329 1.02 (0.98–1.07)
Note that the analyses of MI excluded 167 vaccinated individuals whose MI or zoster occurred before the adjusted start date and 581 unvaccinated
individuals whose MI occurred after the adjusted end date; the analyses of stroke excluded 370 vaccinated individuals whose stroke or zoster occurred
before the adjusted start date and 1,017 unvaccinated individuals whose stroke occurred after the adjusted end date.
ap-Values for interaction: stroke, p = 0.28; MI, p = 0.44.
bIRs age-adjusted in 2-y bands.
doi:10.1371/journal.pmed.1001919.t004
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increased stroke risk in the year following zoster and HZO, respectively, in a Taiwanese cohort
in an administrative database [12,17]. Details about the timing of stroke after zoster were not
available from these studies. A Danish registry cohort study identified an increased stroke risk
during the first year following zoster, with the most pronounced increase being observed in the
first 2 wk following zoster diagnosis, which is consistent with our observations in this current
study [18]. A UK cohort study from general practice reported a long-term increased risk of
transient ischemic attack and MI up to 24 y after acute zoster [9]. The possibility of residual
confounding and the focus on long-term, rather than acute, cardiovascular events mean that
the study provides limited information on the temporality of acute cardiovascular events fol-
lowing zoster.
Our study is a large, population-based cohort of older individuals in the US. Since 98% of
the US population aged 65 y or greater are Medicare beneficiaries, the results of the study are
reasonably generalizable to the older US population. Medicare data include high-quality infor-
mation on demographics, clinical encounters, and prescription drugs. Recent studies have con-
firmed that stroke and MI diagnoses in Medicare have high positive predictive value and
specificity [19,20]. Residual confounding is frequently an issue when using administrative data
for research. However, as our analyses were within-person using the SCCS method, fixed con-
founders are inherently controlled for, and we adjusted finely for increasing age over the obser-
vation period. Residual confounding by unmeasured time-varying factors is unlikely to
produce the effect estimates observed; such factors would need to be associated with both the
timing of zoster and the vascular event and be present in a sufficiently large proportion of
study participants to introduce material confounding. Such factors could plausibly include
major life events or stress. Possible increased ascertainment of vascular events in periods of
close monitoring after zoster could provide an alternative explanation for the associations seen.
However, the scope for any such case-finding bias is limited given that ischemic stroke and
acute MI are associated with significant morbidity, usually resulting in hospitalization, and
hence are unlikely to go undetected. In addition to the standard SCCS analysis, we used an
extended version that allowed for nonrandom censoring of the observation period. The results
were unchanged using the extension, which suggests that any bias due to increased risk of
death as a result of stroke or MI was avoided.
The observed increased risk of stroke and MI following zoster is likely to be explained by
multiple biological mechanisms. Our primary hypothesis is that inflammation may lead to
arterial thrombosis on a background of atherosclerosis. A hemodynamic mechanism is also a
possible basis for the increased risk of stroke following zoster. Acute elevation of blood pressure
[21] relating to zoster-associated pain or stress—or, alternatively, VZV-induced vasculopathy
with arterial rupture or aneurysm formation [7]—could lead to an increased risk of hemor-
rhagic stroke in particular.
Medicare data are administrative data, so misclassification of exposures and outcomes is
possible. However, provided the exposure and outcome are ascertained independently, any
random misclassification in SCCS analyses would tend to bias findings towards the null [22].
We employed a strict definition of herpes zoster, requiring individuals to have received antivi-
ral therapy to reduce misclassification from the possible use of “rule out” codes, whereby possi-
ble herpes zoster is coded as definite herpes zoster, as Medicare is an administrative data
source [11,23]. Use of this definition limited our ability to study the role of antiviral therapy in
stroke and MI rates after zoster. In addition, individuals who receive antiviral therapy are likely
to have more severe zoster; hence, our study findings may be less applicable to individuals with
mild zoster that would not warrant antiviral therapy. Uptake of zoster vaccine was low (9%)
among study participants (all of whom had zoster), with only 3% receiving the vaccine prior to
developing zoster (vaccine failures), and thus even with a very large data source, there was
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limited power to assess whether vaccination modifies the association between zoster and acute
cardiovascular events.
In conclusion, herpes zoster was associated with increased rates of both stroke and MI, with
a particularly marked increase in the first week following zoster diagnosis and tailing off over a
period of 6 mo. The rapid increase in the rate of acute cardiovascular events after zoster diag-
nosis, followed by gradual resolution, is supportive of a causative association. Zoster vaccina-
tion did not appear to modify the association between zoster and ischemic stroke or MI; this
finding requires further study due to low vaccination rates. Our findings provide useful infor-
mation that may help to prevent acute cardiovascular events in older people.
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Editors' Summary
Background
Chickenpox, which is caused by the varicella zoster virus, is a common childhood infec-
tious disease. Although recovery from chickenpox is usually quick, the varicella zoster
virus can persist throughout life inside the nervous system. The dormant virus causes no
symptoms, but if it becomes activated, it causes herpes zoster (also known as shingles or
zoster), a painful skin rash. Anyone who has had chickenpox can develop zoster, but the
condition is most common and most severe in elderly people—half of zoster episodes
occur in people aged more than 60 years. Early signs of zoster include burning or shooting
pain, tingling, and itching. Blister-like sores, which last 1–14 days, then develop on one
side of the face or on one side of the body in a horizontal band. The pain of zoster, which
can be debilitating, can continue for years after the rash disappears—a condition called
post-herpetic neuralgia, which greatly reduces the quality of life. There is no cure for zos-
ter, but vaccination can prevent the condition or lessen its effects, and early treatment with
antivirals may prevent lingering pain by inhibiting viral replication.
WhyWas This Study Done?
Association studies suggest that people have an increased risk of an acute cardiovascular
event—a stroke or a myocardial infarction (MI; heart attack)—in the weeks and months
following a zoster episode. However, these studies mainly compared the incidence of
stroke and MI (the number of strokes and MIs in a given time period) among people who
had had zoster with the incidence among people who had not had zoster and were there-
fore vulnerable to between-person confounding. That is, rather than zoster increasing a
person’s risk of MI or stroke, people who had had zoster may have shared another
unknown characteristic (confounder) that was responsible for their increased risk of MI
and stroke. Here, the researchers investigate whether there is an increased risk of acute car-
diovascular events after zoster using a self-controlled case series study design. Specifically,
they compare the incidence of MI and ischemic stroke in a population of individuals dur-
ing a period of time before and more than a year after the individuals had zoster with the
incidence of MI and ischemic stroke in the same individuals during the weeks and months
right after they were diagnosed with zoster. Because each case is his/her own control,
between-person confounding is avoided.
What Did the Researchers Do and Find?
The researchers identified 42,954 Medicare beneficiaries aged65 years who had had a
zoster diagnosis and an ischemic stroke and 24,237 beneficiaries who had had a zoster
diagnosis and an MI during a five-year period (Medicare is a US government health insur-
ance plan that mainly covers the healthcare costs of elderly individuals; an ischemic stroke
occurs when a blood clot blocks the brain’s blood supply). They then calculated age-
adjusted incidence ratios for stroke and MI during predefined periods up to 12 months
after a diagnosis of zoster relative to the time period before and more than a year after a
diagnosis of zoster (the “baseline” period). Compared to the baseline period, there was a
2.4-fold increased rate of ischemic stroke and a 1.7-fold increased rate of MI in the first
week after zoster. The increased rate of acute cardiovascular events reduced gradually over
the six months following zoster. There was no evidence that MI or ischemic stroke
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incidence ratios differed between individuals who had been vaccinated against zoster (but
still contracted the disease) and those who had not been vaccinated.
What Do These Findings Mean?
These findings suggest that zoster is associated with transiently increased rates of ischemic
stroke and MI. Zoster vaccination—which reduces zoster incidence by half and can reduce
zoster symptoms—was not found to modify the associations between zoster and ischemic
stroke or MI. However, this second finding needs confirmation: the study had limited
power to detect an effect of vaccination on ischemic stroke or MI following zoster, given
the small number of participants who were vaccinated and then developed zoster despite
being vaccinated. Another potential study limitation is residual confounding. Although
the self-controlled case series design controls for time-fixed confounders, time-varying
factors such as major life events or stress may still play a role in the association. Thus, an
episode of zoster may cause stress, which could then lead to an increased risk of MI or
stroke. Importantly, however, these findings enhance our understanding of the magnitude
and timing of the association between zoster and acute cardiovascular events and provide
information that might help to prevent such events in older individuals.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001919.
• The US Centers for Disease Control and Prevention has detailed information about all
aspects of shingles (zoster), including information on vaccination, and information on
stroke and myocardial infarction
• The National Institutes of Health Senior Health website includes information on zoster,
a video describing a personal experience of zoster, and information on stroke and heart
attack
• The UK National Health Service Choices website provides information about all aspects
of zoster and about cardiovascular disease
• MedlinePlus provides links to other resources about zoster, stroke, and heart attack (in
English and Spanish)
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